ArticleLivers2026
The association of cardiovascular disease (CVD) with progression of advanced fibrosis risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Article in Livers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Objective: Advanced fibrosis is the best predictor of future severe liver outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD). Our study aims to determine the association between cardiovascular disease (CVD) with time to a high-risk Fibrosis-4 Index (FIB-4) in patients with low-risk MASLD. Methods: This retrospective cohort study comes from a primary care clinic between 2012 and 2021. The cohort included patients with MASLD and a FIB-4 score at low-risk for advanced fibrosis (<1.3). Patients were followed for the outcome of having a high-risk FIB-4 (≥2.67) or until the end of the study period. The primary predictor variable was CVD, a composite of ICD-9/10 codes for coronary artery, cerebrovascular, and peripheral arterial disease. Covariates included demographic and comorbidity variables. Unadjusted and adjusted Cox regression models were developed for the outcome of time to a high-risk FIB-4 score. Results: The cohort included 859 patients with a mean age of 49.6 years (± 13.7) and mean body mass index of 34.1 (± 8.3) kg/m Conclusion: Our study showed that CVD is associated with an increased risk of progression of FIB-4 scores at low- to high-risk for advanced fibrosis in MASLD patients. Future research investigating how control of cardiometabolic comorbidities impact fibrosis progression in MASLD is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.